227 related articles for article (PubMed ID: 26276528)
1. Patient-reported quality of life after stereotactic body radiotherapy (SBRT), intensity modulated radiotherapy (IMRT), and brachytherapy.
Evans JR; Zhao S; Daignault S; Sanda MG; Michalski J; Sandler HM; Kuban DA; Ciezki J; Kaplan ID; Zietman AL; Hembroff L; Feng FY; Suy S; Skolarus TA; McLaughlin PW; Wei JT; Dunn RL; Finkelstein SE; Mantz CA; Collins SP; Hamstra DA;
Radiother Oncol; 2015 Aug; 116(2):179-84. PubMed ID: 26276528
[TBL] [Abstract][Full Text] [Related]
2. Exploring Value From the Patient's Perspective Between Modern Radiation Therapy Modalities for Localized Prostate Cancer.
Shaverdian N; Verruttipong D; Wang PC; Kishan AU; Demanes DJ; McCloskey S; Kupelian P; Steinberg ML; King CR
Int J Radiat Oncol Biol Phys; 2017 Mar; 97(3):516-525. PubMed ID: 28126301
[TBL] [Abstract][Full Text] [Related]
3. Patient-reported Quality of Life Following Stereotactic Body Radiotherapy and Conventionally Fractionated External Beam Radiotherapy Compared with Active Surveillance Among Men with Localized Prostate Cancer.
Moon DH; Basak RS; Usinger DS; Dickerson GA; Morris DE; Perman M; Lim M; Wibbelsman T; Chang J; Crawford Z; Broughman JR; Godley PA; Chen RC
Eur Urol; 2019 Sep; 76(3):391-397. PubMed ID: 30857758
[TBL] [Abstract][Full Text] [Related]
4. Patient-reported Quality of Life After SBRT, LDR, and HDR Brachytherapy for Prostate Cancer: A Comparison of Outcomes.
Paly JJ; Egleston BL; Wong JK; Burbure N; Sobczak ML; Hayes SB; Chen DYT; Horwitz EM; Hallman MA
Am J Clin Oncol; 2021 Apr; 44(4):131-136. PubMed ID: 33577175
[TBL] [Abstract][Full Text] [Related]
5. Longitudinal assessment of quality of life after surgery, conformal brachytherapy, and intensity-modulated radiation therapy for prostate cancer.
Zelefsky MJ; Poon BY; Eastham J; Vickers A; Pei X; Scardino PT
Radiother Oncol; 2016 Jan; 118(1):85-91. PubMed ID: 26780999
[TBL] [Abstract][Full Text] [Related]
6. Association Between Choice of Radical Prostatectomy, External Beam Radiotherapy, Brachytherapy, or Active Surveillance and Patient-Reported Quality of Life Among Men With Localized Prostate Cancer.
Chen RC; Basak R; Meyer AM; Kuo TM; Carpenter WR; Agans RP; Broughman JR; Reeve BB; Nielsen ME; Usinger DS; Spearman KC; Walden S; Kaleel D; Anderson M; Stürmer T; Godley PA
JAMA; 2017 Mar; 317(11):1141-1150. PubMed ID: 28324092
[TBL] [Abstract][Full Text] [Related]
7. Use, complications, and costs of stereotactic body radiotherapy for localized prostate cancer.
Halpern JA; Sedrakyan A; Hsu WC; Mao J; Daskivich TJ; Nguyen PL; Golden EB; Kang J; Hu JC
Cancer; 2016 Aug; 122(16):2496-504. PubMed ID: 27224858
[TBL] [Abstract][Full Text] [Related]
8. Comparison of quality of life after stereotactic body radiotherapy and surgery for early-stage prostate cancer.
Katz A; Ferrer M; Suárez JF;
Radiat Oncol; 2012 Nov; 7():194. PubMed ID: 23164305
[TBL] [Abstract][Full Text] [Related]
9. Comparative Toxicities and Cost of Intensity-Modulated Radiotherapy, Proton Radiation, and Stereotactic Body Radiotherapy Among Younger Men With Prostate Cancer.
Pan HY; Jiang J; Hoffman KE; Tang C; Choi SL; Nguyen QN; Frank SJ; Anscher MS; Shih YT; Smith BD
J Clin Oncol; 2018 Jun; 36(18):1823-1830. PubMed ID: 29561693
[TBL] [Abstract][Full Text] [Related]
10. Intensity-modulated radiotherapy causes fewer side effects than three-dimensional conformal radiotherapy when used in combination with brachytherapy for the treatment of prostate cancer.
Forsythe K; Blacksburg S; Stone N; Stock RG
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):630-5. PubMed ID: 22099032
[TBL] [Abstract][Full Text] [Related]
11. Health-related quality-of-life changes due to high-dose-rate brachytherapy, low-dose-rate brachytherapy, or intensity-modulated radiation therapy for prostate cancer.
Strom TJ; Cruz AA; Figura NB; Shrinath K; Nethers K; Mellon EA; Fernandez DC; Saini AS; Hunt DC; Heysek RV; Wilder RB
Brachytherapy; 2015; 14(6):818-25. PubMed ID: 26452602
[TBL] [Abstract][Full Text] [Related]
12. [Toxicity and quality of life comparison of iodine 125 brachytherapy and stereotactic radiotherapy for prostate cancers].
Gnep K; Lizée T; Campillo-Gimenez B; Delpon G; Droupy S; Perrier L; de Crevoisier R
Cancer Radiother; 2017 Oct; 21(6-7):478-490. PubMed ID: 28888746
[TBL] [Abstract][Full Text] [Related]
13. Plan quality and dosimetric association of patient-reported rectal and urinary toxicities for prostate stereotactic body radiotherapy.
Qi XS; Wang JP; Gomez CL; Shao W; Xu X; King C; Low DA; Steinberg M; Kupelian P
Radiother Oncol; 2016 Oct; 121(1):113-117. PubMed ID: 27587270
[TBL] [Abstract][Full Text] [Related]
14. Patient-reported outcomes following stereotactic body radiation therapy for clinically localized prostate cancer.
Bhattasali O; Chen LN; Woo J; Park JW; Kim JS; Moures R; Yung T; Lei S; Collins BT; Kowalczyk K; Suy S; Dritschilo A; Lynch JH; Collins SP
Radiat Oncol; 2014 Feb; 9():52. PubMed ID: 24512837
[TBL] [Abstract][Full Text] [Related]
15. Patient-reported quality of life after stereotactic body radiation therapy versus moderate hypofractionation for clinically localized prostate cancer.
Johnson SB; Soulos PR; Shafman TD; Mantz CA; Dosoretz AP; Ross R; Finkelstein SE; Collins SP; Suy S; Brower JV; Ritter MA; King CR; Kupelian PA; Horwitz EM; Pollack A; Abramowitz MC; Hallman MA; Faria S; Gross CP; Yu JB
Radiother Oncol; 2016 Nov; 121(2):294-298. PubMed ID: 27890426
[TBL] [Abstract][Full Text] [Related]
16. Second malignancy probabilities in prostate cancer patients treated with SBRT and other contemporary radiation techniques.
Dee EC; Muralidhar V; King MT; Martin NE; D'Amico AV; Mouw KW; Orio PF; Nguyen PL; Leeman JE
Radiother Oncol; 2021 Aug; 161():241-250. PubMed ID: 34171451
[TBL] [Abstract][Full Text] [Related]
17. Quality of life impact of treatments for localized prostate cancer: cohort study with a 5 year follow-up.
Ferrer M; Guedea F; Suárez JF; de Paula B; Macías V; Mariño A; Hervás A; Herruzo I; Ortiz MJ; Ponce de León J; Sancho G; Boladeras A; Ayala A; Craven-Bratle J; Ávila M; Cunillera O; Pardo Y; Alonso J; Aguiló F;
Radiother Oncol; 2013 Aug; 108(2):306-13. PubMed ID: 23849168
[TBL] [Abstract][Full Text] [Related]
18. Quality of life in patients who underwent 125I brachytherapy, 125I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer.
Nakai Y; Tanaka N; Asakawa I; Anai S; Miyake M; Hori S; Morizawa Y; Tatsumi Y; Hasegawa M; Fujii T; Fujimoto K
J Radiat Res; 2019 Mar; 60(2):270-280. PubMed ID: 30576565
[TBL] [Abstract][Full Text] [Related]
19. Health-related quality of life in men with prostate cancer undergoing active surveillance versus radical prostatectomy, external-beam radiotherapy, prostate brachytherapy and reference population: a cross-sectional study.
Sureda A; Fumadó L; Ferrer M; Garín O; Bonet X; Castells M; Mir MC; Abascal JM; Vigués F; Cecchini L; Suárez JF
Health Qual Life Outcomes; 2019 Jan; 17(1):11. PubMed ID: 30642340
[TBL] [Abstract][Full Text] [Related]
20. Patient reported outcomes among treatment modalities for prostate cancer.
Johnson ME; Zaorsky NG; Martin JM; Ruth K; Greenberg RE; Uzzo RG; Hayes SB; Smaldone MC; Kutikov A; Viterbo R; Chen DY; Hallman MA; Sobczak ML; Horwitz EM
Can J Urol; 2016 Dec; 23(6):8535-8545. PubMed ID: 27995848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]